Advanced Search Close Search
FDA Expands Use of Vonvendi for Von Willebrand Disease
Health

FDA Expands Use of Vonvendi for Von Willebrand Disease

MONDAY, Sept. 8, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved expanded use of Vonvendi (von Willebrand factor [recombinant]) for routine prophylactic use in adults with all types of the blood-clotting disorder von Willebrand disease (VWD), as well as for on-demand treatment of bleeding episodes and perioperative use in children with VWD.

FDA Now Providing Daily Updates on Adverse Events
Health

FDA Now Providing Daily Updates on Adverse Events

  • Updated

FRIDAY, Aug. 29, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is now providing real-time, daily publication updates on adverse event data from its reporting system.